Does dosing frequency of anti-CD20 therapies blunt vaccine responses and increase COVID-19 susceptibility in patients with multiple sclerosis?

Jagannadha Avasarala

doi:10.1111/bcp.16248

Does dosing frequency of anti-CD20 therapies blunt vaccine responses and increase COVID-19 susceptibility in patients with multiple sclerosis?

Jagannadha Avasarala

Research output: Contribution to journal › Comment/debate

Original language	English
Pages (from-to)	3094-3096
Number of pages	3
Journal	British Journal of Clinical Pharmacology
Volume	90
Issue number	12
DOIs	https://doi.org/10.1111/bcp.16248
State	Published - Dec 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Anti-CD20 drugs
B cell repopulation
CD19 cell counts
COVID 19 susceptibility
dosing frequency
multiple sclerosis
vaccine response

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1111/bcp.16248

Cite this

@article{0e3a042e64a448748c32ca409c8e1f70,

title = "Does dosing frequency of anti-CD20 therapies blunt vaccine responses and increase COVID-19 susceptibility in patients with multiple sclerosis?",

keywords = "Anti-CD20 drugs, B cell repopulation, CD19 cell counts, COVID 19 susceptibility, dosing frequency, multiple sclerosis, vaccine response",

author = "Jagannadha Avasarala",

year = "2024",

month = dec,

doi = "10.1111/bcp.16248",

language = "English",

volume = "90",